Cleave Therapeutics

Cleave Therapeutics is a biopharmaceutical company focused on valosin-containing protein (VCP), also known as p97, as a novel target in protein homeostasis and cellular stress pathways for therapeutic use in cancer and neurodegenerative diseases. The privately held company, based in San Francisco, is advancing CB-5339, its second-generation, small molecule VCP/p97 inhibitor, to clinical studies in acute myeloid leukemia (AML), while the National Cancer Institute (NCI) will sponsor and evaluate CB-5339 in clinical studies of patients with solid tumors.

Contact

Scott Harris Chief Operating Officer Phone: 415.713.1713
cleavetherapeutics.com/
92 South Park San Francisco, CA 94107 USA